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Abstract: Background: Cyclin-Dependent Kinases-6 (CDK-6) is a serine/threonine protein kinase 
with regular activity in the cell cycle. Some inhibitors, such as abemaciclib, hymenialdisine, and in-
dirubin, cause cell arrest by decreasing its activity.  
Objectives: The purpose of this study was to evaluate the Molecular Dynamic (MD) effects of abe-
maciclib, hymenialdisine, and indirubin on the structure of CDK-6. 
Methods: The PDB file of CDK-6 was obtained from the Protein Data Bank (http://www.rcsb.org). 
After the simulation of CDK-6 in the Gromacs software, 200 stages of molecular docking were run 
on CDK-6 in the presence of the inhibitors using AutoDock 4.2. The simulation of CDK-6 in the 
presence of inhibitors was performed after docking.  
Results: Abemaciclib showed the greatest tendency to bind CDK-6 via binding 16 residues in the 
binding site with hydrogen bonds and hydrophobic bonding. CDK-6 docked to hymenialdisine and 
indirubin increased the Total Energy (TE) and decreased the radius of gyration (Rg). CDK-6 docked 
to hymenialdisine significantly decreased the coil secondary structure. 
Conclusion: CDK-6 is inhibited via high binding affinity to abemaciclib, hymenialdisine, and indi-
rubin inhibitors and induces variation in the secondary structure and Rg in the CDK-6 docked to the 
three inhibitors. It seems that developing a drug with a binding tendency to CDK6 that is similar to 
those of abemaciclib, indirubin, and hymenialdisine can change the secondary structure of CDK6, 
possibly more potently, and can be used to develop anticancer drugs. However, additional studies 
are needed to confirm this argument.  
Keyword: CDK-6, inhibitors, molecular dynamic, simulation, total energy, abemaciclib, protein data bank. 
1. INTRODUCTION 
Cell cycle regulation plays a crucial role in cell fate. The 
Cyclin-Dependent Kinases (CDKs), a class of ser-
ine/threonine protein kinases, regulate the cell cycle [1]. Cell 
cycle arrest, at any of the phases, i.e. G0/G1, S, G2 and mi-
tosis, increases the likelihood of apoptosis and arrests cell 
growth and proliferation, which is essential for the control of 
cancer cells [2]. Cell cycle arrest provides specific agents 
that play a role in cell damage repair with further opportuni-
ties to evaluate cell performance and confirm cell health [3]. 
In the case of cell genome damage in cell arrest, the DNA 
repair agents will have more time to repair the genome. 
However, if the damage is extremely severe, and the cell is 
unable to repair itself, apoptosis and cell death will occur [4]. 
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The G0/G1 cell phase is the longest and the most impor-
tant phase of cell division, in which the initial cell health is 
evaluated. If the regulatory factors do not detect any disrup-
tion in the cell, cyclin D will increase, causing the phos-
phorylation of CDK4 and CDK6, which in turn leads to the 
phosphorylation and activation of the Rb regulatory protein 
and, therefore, the cell cycle will progress naturally. The Rb 
protein phosphorylation will provide the necessary agents for 
entry into the S phase [5]. CDK-6 plays the most important 
role in controlling and inhibiting cell growth at the beginning 
of the cell cycle and the G0 phase. Therefore, the inhibition 
of this protein can serve as the target of many anticancer 
drugs to prevent cell entry into the first growth and division 
phase [6]. 
The three chemical compounds, abemaciclib, hymeniald-
isine, and indirubin, are known to be potent inhibitors of 
CDKs, that can be used to treat many types of cancers [7]. 
Abemaciclib is a synthetic compound used in many cancers, 
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especially breast cancer, to inhibit CDKs and induce apopto-
sis and cell death [8, 9]. Indirubin is an alkaloid compound 
derived from the fermentation of certain medicinal plants, 
that, by exerting an inhibitory effect on CDKs, can produce 
anti-cancer effects and induce cell apoptosis [10, 11]. Hyme-
nialdisine, which is derived from sea sponges, can produce 
inhibitory effects on CDKs [12]. In fact, abemaciclib, hyme-
nialdisine, and indirubin can inhibit the cell at different 
stages of its growth by inhibiting the activity of CDKs. 
Meanwhile, the study on the effects of molecular dynamics 
of these compounds on CDKs can be useful to develop more 
potent inhibitors. This study aimed to investigate the molecu-
lar dynamic effects of these inhibitors on the CDK6 mole-
cule under simulated conditions and to examine the changes 
induced by these dynamic effects on the structure and prop-
erties of this cell cycle regulating molecule. 
2. MATERIALS AND METHODS 
2.1. PDB Files Preparation  
CDK-6 PDB file (ID: 5L2T) was obtained from the pro-
tein data bank server (www.rcsb.org) and optimized with the 
Arguslab software. Then, the antioxidant files of abemaciclib 
(CID:370), hymenialdisine (CID: 72281), and indirubin 
(CID:10281) were obtained from the Pubchem server which 
were optimized and converted to PDB files by the Arguslab 
software. 
2.2. Simulation and Molecular Dynamics (MD) of CDK-6  
Using the Gromacs version 4.5.4, studies on the molecu-
lar dynamics simulation of the CDK-6 were first performed 
in pure water and then in a G43A1 force field to reach bal-
ance under with changes in temperature and pressure. A 140 
μM concentration was prepared by adding calculated values 
of Na and Cl. The SPC216 model was used in this study 
[12]. Then, the PDB file output was used as a molecular 
docking input to simulate complexes. 
2.3. Molecular Docking 
Molecular docking of abemaciclib, hymenialdisine, and 
indirubin was performed on CDK-6 to find the best binding 
sites for the ligand-receptor and to determine the most stable 
free energy state of the ligand-receptor. In this study, a grid 
box of 60×120×72 nm
3
 (x×y×z) was created for the protein 
after the production of PDBQ and PDBQT for the abemaci-
clib, hymenialdisine, and indirubin molecules as ligands and 
for the CDK-6 molecule as the receptor. We used the autog-
rid4 –p n.gpf –l n.gle Linux command to produce the n.gle 
text file. After 200 runs of molecular docking on ligands, we 
used the Genetic Algorithm and Lamarckian GA parameters. 
The autodock4–p n.dpf–l n.dlg linux command was used to 
produce the n.dlg text file. The data obtained from the n.dlg 
file was analyzed [13, 14]. 
In this study, we used the LigPlot plus v.2.1 software to 
specify the number of hydrophobic bonds and hydrogen 
bonds between CDK-6 with abemaciclib, hymenialdisine, 
and indirubin. The type and number of amino acids present 
in the binding site were determined [15]. 
2.4. Simulation and MD Studies of CDK-6 and Inhibitors 
At the last stage of molecular dynamics simulation, the 
CDK-6 protein complex was formed with abemaciclib, hy-
menialdisine, and indirubin ligands in 140 μM water and salt 
in accordance with the above method. As studied before, the 
paths involved in the simulation were used to analyze the 
structural parameters of the complex. The results of the 
simulation of the CDK-6 molecule alone and its complexes 
with each of these ligands were comparatively analyzed us-
ing the Grapher 10 software [16, 17]. 
The temperature was set at 300K for all the simulations 
and the time of the simulation was 10 nanoseconds (ns). In 
this study, docking and dynamic simulations were performed 
using a 64-bit system with Intel (R) Core (TM) i7 CPU Server. 
2.5. Statistical Methods 
The data were analyzed using SPSS version 22 (Chicago, 
IL, USA). The paired-sample t-test was performed to analyze 
molecular dynamics. P<0.05 was considered the significance 
level.  
3. RESULTS 
Table 1 shows the Binding Energy (BE), Final Intermo-
lecular Energy (FIE), Estimated Inhibition Constant (EIC), 
Table 1. Molecular interactions of abemaciclib, hymenialdisine, and indirubin with CDK-6. 
Interaction Bonds 
Ligand- Receptor 
BE 
kcal/mol 
FIE 
kcal/mol 
EIC 
Hydrogen Bonds Hydrophobic Bonds 
CDK-6 
Abemaciclib 
-8.3 -10.09 820.54 (nM) Arg60, Glu61, Phe164 
Val41, Arg140, Val142, 
Gly165, Val164, Leu68, 
Leu166, Lys43, Asp163, Val45, 
Phe98, Arg44, Leu96 
CDK-6 Hymenialdisine -6.25 -6.85 26.03 (µM) Glu21, Lys43, Asp163 
Asn150, Gln149, Gly20, Ile19, 
Lys29, Asp104, Leu152 
CDK-6 
Indirubin 
-8.33 -9.22 787.54 (nM) Arg60, Val142, Gly165 
Glu61, Val64, Leu68, Arg140, 
Val141, Phe164, Leu166 
Abbreviations: BE; Estimated Free Energy of binding (kcal/mol), FIE; final intermolecular energy (kcal/mol), EIC; estimated inhibition constant (μM). 
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Fig. (1). The analysis of protein–ligand interactions in abemaciclib (A), hymenialdisine (B), and indirubin (C). 
 
and the number of interaction bonds, such as hydrogen bond 
and hydrophobic bonding in CDK-6 in complex with abema-
ciclib, hymenialdisine, and indirubin. 
The interaction bonds (hydrogen bond and hydrophobic 
bonding) between abemaciclib, hymenialdisine, and indiru-
bin and CDK-6 residues are illustrated in Fig. (1). 
The Root Mean-Square Deviation (RMSD) values for the 
simulation of CDK-6 alone and its complexes with abemaci-
clib (blue), hymenialdisine (red) and indirubin (green) at 10 
ns of the simulation are illustrated in Fig. (2). 
Fig. (3) shows the amount of Total Energy (TE) in the 
simulation of CDK-6 alone and its complexes with abemaci-
clib, hymenialdisine, and indirubin at 10 ns of the simula-
tion. 
Fig. (4) shows the value of the radius of gyration (Rg) in 
the simulation of CDK-6 alone and its complexes with abe-
maciclib (blue), hymenialdisine (red) and indirubin (green) 
at 10 ns of the simulation. 
 Molecular dynamics simulation parameters, such as TE, 
RG, and RMSD, of CDK-6 alone and its complexes with 
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Fig. (2). The root mean-square deviation values of CDK-6 alone (black) and its complexes with abemaciclib (blue), hymenialdisine (red) and 
indirubin (green). Statistical analysis was done by the independent-samples t-test. Each point represents mean±SD.
 
 
Fig. (3). Total Energy (TE) of CDK-6 alone (black) and its complexes with abemaciclib (blue), hymenialdisine (red) and indirubin (green). 
Statistical analysis was done by the independent-samples t-test. Each point represents mean±SD. 
 
 
Fig. (4). Radius of gyration (Rg) of CDK-6 alone (black) and its complexes with abemaciclib (blue), hymenialdisine (red) and indirubin 
(green). Statistical analysis was done by the independent-samples t-test. Each point represents mean±SD. 
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Table 2.  Molecular dynamics simulation parameters of CDK-6 complexes with inhibitors. 
Simulation Parameters 
Inhibitors 
TE RG RMSD 
CDK6 -337336(2502) 1.87(0.02) 0.23(0.03) 
CDK6-Abemiciclib -314797(3438)* 1.88(0.01)* 0.18(0.03)* 
CDK6-Hymenialdisine -314594(3441)* 1.83(0.02)* 0.19(0.03)* 
CDK6-Indirubin -313994(3328)* 1.84(0.01)* 0.17(0.02)* 
TE; Total Energy, RG; Radius of gyration, RMSD; Root-Mean-Square Deviation. Statistical analysis was done by the independent-samples t-test. Each point represents mean±SD;  
*P < 0.001 compared with CDK-6. 
 
Table 3.  Variation in the secondary structure of CDK-6 in complex with ligands. 
Secondary 
Structure 
Protein-Ligand 
Coil 
% 
B-Sheet 
% 
B-Bridge 
% 
Bend% 
Turn 
% 
A-Helix 
% 
3-Helix 
% 
CDK6 24.2 14.6 1.2 13.1 10.8 33.8 2.3 
CDK6-Abemiciclib 24.1 14.2 1.2 14.1 11.6 32.8 2.0 
CDK6- Hymenialdisine 23.2 14.9 1.2 14.0 10.9 33.3 2.5 
CDK6- Indirubin 24.1 14.6 1.4 13.4 11.3 33.1 2.1 
 
abemaciclib, hymenialdisine, and indirubin, at 10 ns of the 
simulation are shown in Table 2. 
Variation in the secondary structure of the CDK-6 pro-
tein, as a factor to predict CDK-6 activity in complex with 
abemaciclib, hymenialdisine, and indirubin at 10 ns of the 
simulation is shown in Table 3. 
4. DISCUSSION 
This study shows that abemaciclib, hymenialdisine, and 
indirubin, as the three inhibitors of CDKs, can bind to CDK-
6 with high tendency and can induce structural changes in 
this serine/threonine protein kinase, influencing the cell cy-
cle. Abemaciclib is one of the potent CDK-6 inhibitors [18]. 
In this study, abemaciclib showed a higher tendency to bind 
CDK-6 than indirubin and hymenialdisine. It forms 3 hydro-
gen and 13 hydrophobic bonds with CDK-6 in the binding 
site. This compound, with lowest concentration (820.54 nM), 
releases 8.3 Kcal/mol (BE=-8.3 Kcal/mol) in the presence of 
CDK-6 (Fig. 1 & Table 1). Abemaciclib is an oral, potent, 
small inhibiting molecule of CDK4 and CDK6 activity, 
which blocks retinoblastoma tumor suppressor protein phos-
phorylation and thereby prevents the progression of cancer 
through the cell cycle [19]. The sea sponge constituent, hy-
menialdisine, is a potent inhibitor of cyclin-dependent 
kinases, glycogen synthase kinase-3β and casein kinase 1 
[20]. Hymenialdisine and indirubin bind to CDK-6 with 3 
hydrogen and 7 hydrophobic bonds in different binding sites 
(Fig. 1), but their binding tendency to CDK-6 differs. Indiru-
bin binds to CDK-6 (BE=-8.33 Kcal/mol) with a higher ten-
dency and lower concentration (787.54 nM) than hymeniald-
isine (BE=-6.25 Kcal/mol and concentration of 26.03 µM) 
(Table 1). Not only abemaciclib, hymenialdisine and indiru-
bin also bind to CDK-6 with high tendency but they also 
inhibit cell cycle by exerting an effect on CDKs and decreas-
ing their activity [21]. The simulation of CDK-6 alone and 
its complexes with three CDK inhibitors stabled after 8 ns. 
The RMSD of all significantly decreased after simulation in 
the presence of the inhibitors (Table 2), which helped to re-
duce the activity of CDK-6 [15, 22]. Abemaciclib causes the 
TE to increase from -337336±2502 (CDK-6 simulation in 
the absence of abemaciclib) to -314797±3438 (CDK-6 simu-
lation in the absence of abemaciclib) significantly by binding 
to and inhibiting CDK-6. This increase in the TE is also sig-
nificant for hymenialdisine and indirubin (Fig. 3 & Table 2). 
This study shows that, although hymenialdisine showed a 
lower tendency to bind to CDK-6 than indirubin and abema-
ciclib, it decreases the Rg of CDK-6 strongly. Hymenialdis-
ine and indirubin decrease the Rg at 10 ns of the simulation 
compared with the simulation in CDK-6 alone. Rg is a 
measure of the protein radius. For globular proteins, high Rg 
means low compaction and higher function of the protein 
structure. Decreased Rg in the binding of hymenialdisine and 
indirubin to CDK-6 decreases the availability of the active 
sites and its activity [23]. Variation in the secondary struc-
ture of CDK-6 increased when abemaciclib, hymenialdisine, 
and indirubin docked to CDK-6 (Table 3). Decrease in the 
coil in all the complexes of CDK-6 with three inhibitors, 
especially hymenialdisine, and other variations in the α-
Helix and β-Sheet structures show that these inhibitors affect 
the secondary structure of CDK-6. 
CONCLUSION 
CDK-6 is one of the most important serine/ 
threonine protein kinases that strongly inhibits cell cycle 
after inhibitors, such as abemaciclib, hymenialdisine, and 
indirubin decrease its activity. This study showed that the 
high binding affinity of these inhibitors to CDK-6 led to the 
inhibition of the spontaneous reactions and decrease in the 
released free energy. These three compounds cause changes 
in the secondary structure of CDK6 that may play a role in 
140    Current Drug Research Reviews, 2019, Vol. 11, No. 2 Basati et al. 
inhibiting it. Abemaciclib and indirubin docked to CDK6 at 
lower doses in comparison with hymenialdisine, while hy-
menialdisine decreases Rg in comparison with two other 
drugs and increases the secondary coil active structure. It 
seems that developing a drug with a binding tendency to 
CDK6 that is similar to those of abemaciclib, indirubin, and 
hymenialdisine can change the secondary structure of CDK6, 
possibly more potently, and can be used to develop antican-
cer drugs. However, additional studies are needed to confirm 
this argument. 
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